Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-02-02
2010-02-09
Woodward, Cherie M (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S004000
Reexamination Certificate
active
07659087
ABSTRACT:
A method is provided for determining the severity of appendicitis in a patient that includes testing a blood, serum or plasma sample from the patient for the quantity of MRP8/14 in the sample and comparing it with the quantity of MRP8/14 present in standard samples correlated with an appendicitis severity scoring system. A histologically-based appendicitis severity scoring system is also provided. Immunoassays and kits for performing the appendicitis assays of this invention are also provided, as are standard samples and data correlating MRP8/14 quantities present in patient samples to histologically-based appendicitis severity grades. The methods and immunoassay devices and kits of this invention are useful for managing the treatment of patients presenting with appendicitis symptoms.
REFERENCES:
patent: 4493795 (1985-01-01), Nester, Jr. et al.
patent: 4833074 (1989-05-01), Fagerhol et al.
patent: 5055389 (1991-10-01), Bar-or et al.
patent: 5350687 (1994-09-01), Odink et al.
patent: 5455160 (1995-10-01), Fagerhol et al.
patent: 5470750 (1995-11-01), Bar-Or
patent: 5552295 (1996-09-01), Stanker et al.
patent: 5702920 (1997-12-01), Odink et al.
patent: 6451550 (2002-09-01), Eckersall
patent: 6749565 (2004-06-01), Chundner
patent: 2003/0224452 (2003-12-01), Colgin et al.
patent: 2004/0121343 (2004-06-01), Buechler et al.
patent: 2004/0175754 (2004-09-01), Bar-Or et al.
patent: 2004/0241775 (2004-12-01), Romero et al.
patent: 2005/0095249 (2005-05-01), Hanash
patent: 2009/0155813 (2009-06-01), Colgin et al.
patent: EP 0263072 (1988-04-01), None
patent: 0 428 080 (1991-05-01), None
patent: 058201 (1994-03-01), None
patent: WO 98/35985 (1998-08-01), None
patent: WO 00/26668 (2000-05-01), None
patent: WO 03/069349 (2003-08-01), None
patent: WO 2004/032711 (2004-04-01), None
patent: WO 2004/057341 (2004-07-01), None
patent: WO 2004/059293 (2004-07-01), None
patent: WO2006/012588 (2006-02-01), None
Yui et al., Biol Pharm Bull. Jun. 2003;26(6):753-760.
Power et al., Br J Surg. Apr. 2005;92(Suppl 1):97-98.
FDA Guidance—Class II Special Controls Guidance Document: Fecal Calprotectin Immunological Test Systems, issued on Jul. 27, 2006.
APPYSCORE Trademark SN 7704421 (2006).
Birchley, D. (2006) “Patients with Clinical Acute Appendicitis Should Have Pre-Operative Full Blood Count and C-Reactive Protein Assays,”Ann. R. Coll. Surg. Engl.88:27-32.
Maruniak et al. (1987) “Acute Phase Reactants in Inflammatory Conditions of the Colon Relationship with Nerve Hypertrophy,”Fed. Proc.46(3):986, Abstract No. 3900.
Sack et al. (2006) “Diagnostic Value of Blood Inflammatory Markers for Detection of Acute Appendicitis in Children,”BMC Surg.6:15.
Supplementary Partial European Search Report, Corresponding to European Application No. 05 77 5574, Completed on Jan. 14, 2008.
Yang et al. (2006) “Laboratory Tests in Patients with Acute Appendicitis,”ANZ J. Surg.76:71-74.
Cell Sciences. Human Calprotectin ELISA Kit. 2006, IN: Cell Sciences, Inc. datasheet. Retrieved online at <<URL: http ://www.cellsciences.com/content/p-detail.asp?rowid=8403>>.
Cell Sciences. Anti-human S100A8.A9 (MPR-8/MPR-14), Calprotectin, Clone 27E10, Monoclonal Antibody. 2006, IN: Cell Sciences Inc. datasheet. Retrieved online at <<URL: http://www.cellsciences.com/content/p-detail.asp?rowid=7581>>.
Aadland et al. (2002) “Faecal Calprotectin: A Marker of Inflammation Throughout the Intestinal Tract,”Eur. J. Gasroenterol Hepatol. 14:1823-825.
Ahlquist et al. (1996) “Stool Markers for Colorectal Screening: Future Considerations,”Dig. Dis.14(3):132-144.
Alic, M. (1999) “Is Fecal Calprotectin the next Standard in Inflammatory Bowel Disease Activity Test,” (letter)Am. J. Gastroenterol.94(11):3370-3371.
Arnott et al. (2002) “Review Article: Is Clinical Remission the Optimum Therapeutic Goal in the Treatment of Crohn's Disease,”Aliment Pharmacol. Ther.16:857-867.
Arredouani et al. (2005) “Haptoglobin Dampnes Endotoxin-Induced Inflammatory Effects Both In Vitro and In Vivo, ”Immunology114(2):263-271.
Avrameas et al. (1978) “Coupling of Enzymes to Antibodies and Antigens, ”Scand. J. Immunol.8(7):7-23.
Barcia et al. (Dec. 2002) “Neutrophil Count in Normal Appendix and Early Appendicitis: Diagonstic Index of Real Acute Inflammation,”Ann. Diag. Path.6(6):352-356.
Berger et al. (1997) “Time-Scale of Interleukin-6, Myeloid Related proteins (MRP), C Reactive Protein (CRP, and Endotoxin Plasma Levels During the Postoperative Acute Phase Reaction,”Shock7(6):422-426.
Berntzen et al. (1991) “Calprotectin (The L1 Protein) During Surgery in Patients with Rheumatoid Arthritis,”Scand. J. Clin. Lab. Invest.51(7):643-650.
Berntzen et al. (1991) “The L1 Protein as a New Indicator of Inflammatory Activity in Patients with Juvenile Rheumatoid Arthritis,”J. Rheumatol.18(1):133-138.
Berntzen et al. (1989) “A Longitudinal Study of the Leukocyte Protein L1 as an Indicator of Disease Activity in Patients with Rheumatoid Arthritis,”J. Pheumatol.16(11):1416-1420.
Berntzen et al. (1988) “The Major Leukocyte Protein L1 as an Indicator of Inflammatory Joint Disease,”Scand. J. Rheumatol.Supp 76:251-256.
Berntzen et al. (1991) “The Leukocyte Protein L1 in Plasma and ynovial Fluid from Patients with Rheumatoid Arthritis and Osteoarthritis,”Scand J. Rheumatol.20(2):74-82.
Berstad et al. (2000) “Relationship Between Intestinal Permeability and Calprotectin in Gut Lavage Fluid,”Scand J. Gastroenterol.35(1):64-69.
Bjarnason et al. (2001) “Fecal Calprotectin: A Significant Step in the Noninvasive Assessment of Intestinal Inflammation,”J. Pediat. Gastroent.Nutr.33:11-13.
Bjerke et al. (1993) “Distribution of Macrophages and Granulocytes Expressing L1 Protein (Calprotectin) in Human Peyer's Patches Compared with Normal Ileal Lamina Propria and Mesenteric Lymph Nodes,”Gut34(10):1357-1363.
Bogumil et al. (1998) “Serum Levels of Macrophage-Derived Protein MRP8/14 are Elevated in Active Multiple Sclrosis,”Neurosci. Lett.247(2-3):195-197.
Bonaldo et al. (1996) “Normalization and Subtraction: Two Approaches to facilitate Gene Discovery,”Genmome Res.6:791-806.
Brandtzaeg et al. (1987) “Distribution of a Formalin-Resistant Myelomonocytic Antigen (I1) in Human Tissues. I. Comparison with Other Leukocyte Markers by Paired Immunofluorescence and Immunoenzyme Staining,”Am. J. CLin. Pathol.87(6):681-699.
Brandtzaeg et al. (1987) “Distribution of a Formalin-Resistant Myelomonocytic Antigen (I1) in Human Tissues. II. Normal and Aberrant Occurrence in Various Epithelia,”Am. J. Clin. Pathol.87(6):700-707.
Brantzaeg et al. (1992) “The Leucocyte Protein L1 (Calprotectin): Usefulness as an Immunohistochemical Marker Antigen and Putative Biological Function,”Histopathol.21(2):191-196.
Brun et al. (1994) “Sjögren's Syndrom in Inflammatory Rheumatic Disease: Analysis of the Leukocyte Protein Calprotectin in Plasma and Saliva,”Scand. J. Rheumatol.23(3):114-118.
Brun et al. (1992) “Calprotectin in Patients with Rheumatoid Arthiritis: Relation to Clinical and Laborotory Variables of Disease Activity,”J. Rheumatol.19(6):859-862.
Brydon et al. (2001) “Faecal Calprotectin Levels and Colorectal Neoplasia,”Gut48(4):579-580.
Bunn et al. (2001) “Fecal Calprotecin as a Measure of Disease Activity in Childhood Inflammatory Bowel Disease,”J. Pediat. Gastroenterol. Nutr.32(2):171-177.
Bunn et al. (2001) “Fecal Calprotectin: Validation as a Nonivasive Measure of Bowel Inflammation in Childhood Inflammatory Bowel Disease,”J. Pediat. Gastroenterol. Nutr.33(1):14-22.
Burkhardt et al. (2001) “An Increase in Myeloid-Related Protein Serum Levels Precedes Acute Renal Allograft Rejection,”J. Am. Soc. Nephrol.12:1947-1957.
Clark et al. (1990) “Calg
Bealer John F.
Colgin Mark A.
Donnelly Richard G.
AspenBio Pharma, Inc.
Greenlee Winner and Sullivan P.C.
Woodward Cherie M
LandOfFree
Methods and devices for diagnosis of appendicitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and devices for diagnosis of appendicitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and devices for diagnosis of appendicitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4191746